Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry.
Uchiyama S, Shibata Y, Hirabayashi T, Mihara B, Hamashige N, Kitagawa K, Goto S, Origasa H, Shimada K, Kobayashi H, Isozaki M, Ikeda Y; J-TRACE Investigators. Uchiyama S, et al. Among authors: goto s. J Stroke Cerebrovasc Dis. 2010 May;19(3):190-197. doi: 10.1016/j.jstrokecerebrovasdis.2009.04.004. J Stroke Cerebrovasc Dis. 2010. PMID: 20434045
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.
Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Goto S, et al. Eur Heart J. 2010 Nov;31(21):2601-13. doi: 10.1093/eurheartj/ehq320. Epub 2010 Aug 30. Eur Heart J. 2010. PMID: 20805115 Free PMC article. Clinical Trial.
Panel discussion.
Shigematsu H, Uchiyama S, Goto S. Shigematsu H, et al. Among authors: goto s. Drugs. 2010 Nov 1;70 Suppl 1:15-22. doi: 10.2165/00000006-000000000-00000. Drugs. 2010. PMID: 20977288 English, Japanese. No abstract available.
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.
Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL; LANCELOT-CAD Investigators. Wiviott SD, et al. Among authors: goto s. Circulation. 2011 May 3;123(17):1854-63. doi: 10.1161/CIRCULATIONAHA.110.001404. Epub 2011 Apr 18. Circulation. 2011. PMID: 21502571 Clinical Trial.
One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE).-.
Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H; J-TRACE Investigators. Goto S, et al. Circ J. 2011;75(11):2598-604. doi: 10.1253/circj.cj-11-0378. Epub 2011 Aug 20. Circ J. 2011. PMID: 21857143 Free article. Clinical Trial.
Rivaroxaban in patients with a recent acute coronary syndrome.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Mega JL, et al. Among authors: goto s. N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077192 Free article. Clinical Trial.
One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after STroke) registry.
Suzuki N, Sato M, Houkin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Origasa H, Miyamoto S, Minematsu K, Matsumoto M, Okada Y. Suzuki N, et al. Among authors: goto s. J Stroke Cerebrovasc Dis. 2012 May;21(4):245-53. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.010. Epub 2012 Feb 24. J Stroke Cerebrovasc Dis. 2012. PMID: 22365283
3,594 results